Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Protagonist Therapeutics (PTGX) over the last 9 years, with Q1 2025 value amounting to -$5000.0.

  • Protagonist Therapeutics' Gains from Investment Securities changed N/A to -$5000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $30.2 million, marking a year-over-year increase of 77795.23%. This contributed to the annual value of $7.8 million for FY2024, which is 132.4% down from last year.
  • Latest data reveals that Protagonist Therapeutics reported Gains from Investment Securities of -$5000.0 as of Q1 2025.
  • Protagonist Therapeutics' Gains from Investment Securities' 5-year high stood at $30.2 million during Q4 2024, with a 5-year trough of -$5000.0 in Q1 2025.
  • Over the past 5 years, Protagonist Therapeutics' median Gains from Investment Securities value was $6.6 million (recorded in 2022), while the average stood at $8.2 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 587.55% in 2022, then skyrocketed by 28107.59% in 2024.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Gains from Investment Securities stood at $5.9 million in 2021, then increased by 9.35% to $6.4 million in 2022, then rose by 22.99% to $7.9 million in 2023, then soared by 281.08% to $30.2 million in 2024, then plummeted by 100.02% to -$5000.0 in 2025.
  • Its Gains from Investment Securities stands at -$5000.0 for Q1 2025, versus $30.2 million for Q4 2024 and $7.9 million for Q4 2023.